Notice of allowance issued for two Canadian patent applications and US Congressman Bill Foster visits Midwestern University

Saturday, March 31, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NAPERVILLE, Ill., March 30, 2018 /PRNewswire/ -- Pharmazz, Inc. is pleased to announce that Notice of Allowance has been

issued for Canadian Patent Application No. 2696398 titled "Methods for treatment of stroke or cerebrovascular accidents using an ET-B receptor agonist." PMZ-1620, a selective endothelin-B receptor agonist, is in clinical phase II trials in patients suffering
from cerebral ischemia (stroke) and mild to moderate Alzheimer's disease. The company also announces that another Notice of Allowance has been issued for Canadian Patent Application No. 2759791 titled "Novel therapeutic treatments using centhaquin." PMZ-2010 (centhaquin) is advanced stages of clinical phase II trial in patients with hypovolemic shock. The company expects to have interim results before June 2018.

US Congressman Bill Foster visited Midwestern University, Downers Grove, IL and met with Dr. Anil Gulati and his team. Dr. Gulati presented research and development efforts at the University that led to the formation of Pharmazz, Inc. "I am pleased we have a world class medical training and research university with a beautiful campus right here at Midwest," Congressman Foster said. "This University conducts research that could be transformative to patients with Alzheimer's disease, are recovering from strokes or spinal injury, and individuals who struggle with dependency.  Collaboration with companies like Pharmazz, Inc. will lead the way to commercializing new discoveries and treatments."

About Pharmazz, Inc.  Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website,  

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.

ContactPharmazz, Inc.   Shruti 


Cision View original content:

SOURCE Pharmazz, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store